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Summary Twenty five hormone manipulated patients with prostate cancer and metastatic bone disease,
treated at least 6/12 previously by hormone manipulation, were given intravenous infusions of Disodium
Pamidronate (APD) over a 6 month period. Patients received 30 mg weekly for 4 weeks then twice monthly
for 5 months. No other treatment was administered during study. Eleven of 17 patients with pain at the start
of the study were pain free at the end. Fasting morning calcium excretion and serum osteocalcin fell
significantly with Pamidronate (P<0.0001) and urine hydroxyproline was lowered in 13/20 evaluable patients
at 6 months. Alkaline phosphatase fell in a proportion of patients and five of 17 patients with previously
progressive bone scans stabilised (4) or regressed (1) on treatment. Rising acid phosphatase levels were also
lowered in five patients. It is concluded that Pamidronate may be effective in palliating bone pain in some
patients and has a stabilising influence on abnormally high bone turnover in metastatic prostate cancer.
Further controlled studies of the compound are now warranted.
Morbidity and mortality in prostate cancer, the third most
common cause of male cancer death in the United Kingdom
(Waxman 1985) is generally related to the presence of bony
metastases (VACURG 1976; Labasky & Smith 1988) which
are identified in up to 84% of patients dying from the disease
(Abrams et al., 1950). Although such metastases are classical-
ly described as osteoblastic in character recent work has
shown that abnormally high levels of bone resorption occur
concurrently with new bone formation (Percival et al., 1987).
Histological studies confirm that increased erosion is present
in both tumour free and infiltrated bone (Urwin et al., 1985)
and that within resorption may be mediated both by in-
creased osteoclast activity and the direct action of neoplastic
cells (Galasko 1976).
The bisphosphonate 3-Amino 1-Hydroxypropylidene-l, 1-
Bisphosphonate (Pamidronate) is an inhibitor of osteoclast
mediated osteolysis (Fleisch 1983) effective in the treatment
of malignant hypercalcaemia (Sleeboom et al., 1983). It has
proved to be valuable in the palliative treatment of metas-
tatic breast carcinoma, decreasing the overall incidence of
morbidity (Van-Holten Verzantvoort et al., 1987) and pro-
ducing sclerosis in previously lytic deposits (Morton et al.,
1988). In the light of this experience this preliminary report
examines the use of Pamidronate in patients with metastatic
prostate cancer with reference to its subjective effect on
patient morbidity and its objective efficacy in controlling
disturbed metabolic bone function.
Patients and methods
Twenty five patients (62 to 87 years, mean 71.3) with his-
tologically proven prostate cancer and evidence of bone
metastases on skeletal scintigraphy were admitted to the
study. Each had undergone hormone manipulation by orchi-
dectomy or LHRH analogue therapy at least 6 months
previously and the mean interval before commencement of
bisphosphonate therapy was 23.4 months. Informed consent
having been obtained, intravenous Pamidronate (30 mg in
500 ml of normal saline infused over 3 h) was administered
weekly for 4 weeks and continued twice monthly for 5
months or until patient death or withdrawal. At each visit to
the dedicated Pamidronate clinic patients were interviewed by
the same investigator (NC) and scores on a 6 point pain scale
were recorded. Mobility was assessed using the Karnofsky
performance scoring system.
Metabolic bone activity was monitored immediately prior
to treatment and monthly thereafter. Blood was drawn for
serum alkaline phosphatase and osteocalcin* and fasting
morning urine was collected in aliquots for estimation of
hydroxyproline/creatinine ratiost. In 11 cases with advancing
disease at study entry, urinary samples were also analysed for
urinary calcium excretion (CaE) (Nordin et al., 1976). During
a lead in period of 6 months skeletal scintigraphy and com-
plimentary focal radiology were undertaken and subsequently
repeated immediately prior to and following completion of
bisphosphonate treatment. Scan deterioration was defined as
any increase in either the size or number of identified lesions;
all scans and plain films were assessed serially at the end of
the study. Tumour behaviour was monitored during the lead
in period and every 4 weeks on study by assay of serum
tartrate labile prostatic acid phosphatase. Statistical analysis
was by one way repeated measures analysis of variance.
Ethical approval for the study was provided by the hospital
ethical committee.
Results
Infusions were well tolerated and there were no significant
side effects arising from the treatment. Four patients died
during the 6 month study period and one was too ill to
continue after 5 months therapy.
Pain andmobility
Eight of 25 patients were pain free at entry: all remained pain
free on treatment. Eleven of 17 patients with pain at the start
of the trial had an improvement in their pain score with
treatment. Six of 10 patients with mild to moderate pain
became pain free by 3 months and none of these deteriorated
thereafter. By 6 months three of these patients had died but
pain was either better (two) or no worse (one) than at study
entry. Seven patients had severe pain at the onset of treat-
ment. One of these died with increased pain at 3 months
whilst pain in five others improved by at least one grade with
Pamidronate (additional local radiotherapy was required for
one patient with persistent shoulder pain). Performance
scores (Table I) broadly paralleled improvements in observed
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Table I Five Point Pain Scores left margin and Karnofsky
performance status () right margin
Karnofsky
Pre Performance
Pain Score Treatment 3 Months 6 Months Indicator
0 8 (8) 15 (16) 12 (15) (100)
1-2 10 (10) 6* (2) 8* (2) (80-90)
3-4 7 (7) 3 (5) 0 (3) 50-70)
5 0 (0) 0 (1) 0 (0) (20-40)
Evaluable
Patients 25 24 20
*Focal palliative radiotherapy in one patient.
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pain scores. After 6 months 15 of 20 evaluable patients
enjoyed no restriction of movement or mobility.
Metabolic bone activity
Fasting morning urine Hydroxyproline/Creatinine ratios
(OHP/Cr) are plotted for those patients with high (Figure la)
and normal (Figure lb) levels at the onset of treatment. Data
was incomplete in one patient. Fasting urine calcium excre-
tion (Figure lc) fell significantly (P<0.0001 at 4 weeks) in
all cases despite variable patterns of hydroxyproline excre-
tion: this difference was maintained at 6 months. Analysis of
mean serum osteocalcin in the same patients (Figure 2)
showed that significant supression occurred after 3 months
(P<0.0001) and was maintained thereafter. Alkaline phos-
phatase, initially raised in 18 patients (Figure 2) fell in 12 by
3 months, but at 6 months levels had begun to rise again in
five. Eight further patients with normal levels at the outset
(not illustrated) remained within the normal range through-
out treatment.
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Figure 1 Indices of bone turnover. Patients with (a) initially high
and (b) initially normal Fasting Morning Urine Hydroxyproline/
Creatinine Ratio (OHP/Cr). (c) Fasting Urinary Calcium Excre-
tion (CaE, Mean ± 95% CL). Broken line: upper limit of normal.
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Figure 2 Indices of bone formation. (a) Patients with initially
high Alkaline Phosphatase and (b) Serum Osteocalcin
(Mean ± 95% CL). Eight patients with initially normal Alkaline
Phosphatase are not illustrated. Broken line: upper limit of nor-
mal.
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Bone scintigraphy and tumour markers
Four of 16 patients with deteriorating bone scans during the
lead in period showed stabilisation of scan appearances (no
increase in size or number oflesions) and one patient demon-
strated objective scintigraphic improvement. Six patients
showed progression and five died or withdrew from study
(presumed progression). Only one of nine patients with
initially stable scans deteriorated on treatment. Attempted
quantification of radiological change induced by Pamid-
ronate therapy was unsuccessful. Six of 11 patients whose
acid phosphatase was above the upper limit of normal during
the lead in period showed a fall at the onset of treatment
with Pamidronate (Figure 3). Levels continued to rise in the
remaining five patients.
Discussion
Recognition that substantially increased bone resorption may
occur in the presence of osteoblastic metastases has provided
the rationale for the use of inhibitors of bone resorption in
prostatic malignancy (Galasko 1976; Urwin et al., 1985; Per-
cival et al., 1987). Apart from two recent letters relating to
Pamidronate therapy (Masud & Slevin 1989; Pelger et al.,
1989) experience with bisphosphonates in prostate cancer has
been limited to reports using earlier generation compounds;
1-Hydroxy Ethylidene-l 1-Bisphosphonate (Etidronate) dim-
inished urinary OHP/Cr and CaE (Urwin et al., 1984) whilst
Dichloromethylene Bisphosphonate (Clodronate), provided
short term relief of bone pain (Adami et al., 1985). In this
preliminary study the efficacy of Pamidronate (which, unlike
earlier bisphosphonates, will inhibit osteoclasts at doses with
a minimal effect on bone mineralisation: Reitsma et al., 1983)
has been examined in terms of subjective pain relief and
objective measurable change in skeletal metabolic function.
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During the 6 month study period measurable improve-
ments in pain and mobility were recorded. Although four
patients died of advancing disease, in three of these bone
pain remained well controlled and was not the predominant
clinical problem during the terminal phase. Clearly, whilst
these observations appear to suggest enhanced quality oflife,
the possible placebo effect of intensive support in the prostate
cancer clinic and the subjective nature of pain relief demand
that further controlled studies will be required to determine
accurately the analgesic properties of this class of compound.
Although most patients demonstrated treatment-induced
falls in urinary hydroxyproline levels (Figure la and lb) - a
finding consistent with ongoing supression of pathological
bone destruction - continuing elevation in others suggested a
failure to reduce bone destruction. In such cases, the pos-
sibility that significant inhibition of the osteoclast resorption
known to occur in the non-metastatic peripheral skeleton
(Urwin et al., 1985), is being masked by overwhelming direct
tumour-driven bone destruction within the metastasis itself
cannot be discounted. By contrast, fasting urinary CaE (Fig-
ure 1c) reduced in all cases regardless of the hydroxyproline
excretion pattern. Serum osteocalcin also fell in all patients
- albeit at a slower rate than urinary calcium excretion -
whilst serum alkaline phosphatase demonstrated an inconsis-
tent pattern. Dissociation in the levels of these two markers
has been reported in Paget's disease of bone (Delmas et al.,
1986) (a condition also associated with rapid bone formation)
and probably reflects focal osteoblast dysfunction with im-
paired osteocalcin production in areas of high bone turnover.
These observations illustrate that, whilst Pamidronate treat-
ment exerts a significant and beneficial effect on bone metab-
olism in patients with prostate cancer, the complex changes
occuring within the skeleton are unlikely to be explained by
analysis of serum and urine data alone; direct histomor-
phometric measurements of metastatic and tumour free bone
will be required to understand the precise mode of action of
bisphosphonate therapy in this condition.
It was not surprising that, in contrast to recent studies in
breast cancer (Morton et al., 1988), it proved impossible to
quantify changes in radiologically detected bone sclerosis; the
essentially osteoblastic nature of prostatic cancer ensured
that appearances could not be objectively verified by X-ray
analysis alone. On the other hand, scintigraphic appearances
are acknowledged as an effective tool for determination of
progression or regression in metastatic prostate cancer (Gal-
asko, 1986); in this study a confident diagnosis of improve-
ment was made in five patients who were known to be
deteriorating in the 6 months prior to treatment. Further-
more, the time lapse following hormonal manipulation en-
sured that any observed bone scan changes were likely to be
due to Pamidronate treatment rather than the endocrine
therapy. These findings are in keeping with disease stabilisa-
tion in bone although further controlled studies including
bone histology, will be required to define the exact mechan-
isms underlying these observations.
Pamidronate therapy induced a fall in tumour markers in a
number of patients with rising acid phosphatase levels prior
to treatment; palliative radiotherapy may have accounted for
this observation in one patient, but in the remainder the
change correlated exactly with the onset of anti-osteoclast
therapy. Decreases in tumour marker levels have been re-
ported in cases of metastatic breast cancer treated with
Pamidronate (Morton & Howell 1988): although it is possible
to postulate that such observations are due to direct anti-
tumour activity or to inhibition of the release of tumorigenic
substances from the resorbing bone surface (Manishen et al.,
1986) further work will be required to support this hypo-
thesis.
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Figure 3 Eleven patients with high Prostatic Acid Phosphatase
before the onset of treatment. * Denotes focal palliative radio-
therapy prior to treatment. Fifteen patients had normal acid
phosphatase at start of treatment.
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